Synthesis, characterization, and in vitro cytocompatibility of Ga-bioactive glass/polymer hydrogel composites
Source abstract
Abstract
A bioactive glass series (0.42SiO 2 -0.10Na 2 O-0.08CaO-(0.40– x)ZnO-( x)Ga 2 O 3 ) was incorporated in carboxymethyl cellulose–dextran hydrogels at three different loadings (0.05, 0.10, and 0.25 m 2 ), and the resulting composites were characterized using scanning electron microscopy, physical swelling characteristics, and inductively coupled plasma optical emission spectroscopy. In vitro cytocompatibility was also evaluated for composite extracts in contact with L-929 mouse fibroblasts and MC3T3-E1 human osteoblasts. Scanning electron microscopy confirmed that glass particles were distributed throughout the hydrogels, and swelling studies showed that glass presence can increase the amount of fluid that can be absorbed by the hydrogels after seven days of immersion in phosphate-buffered saline by up to 180%. Several trends were observed in the inductively coupled plasma optical emission spectroscopy data, with the most important being the release of Ga 3+ from both Ga-containing glasses at all three loadings, with a maximum of 4.7 mg/L released after 30 days of incubation in phosphate-buffered saline. Cell viability analysis suggested that most composite extracts did not decrease neither fibroblast nor osteoblast viability. These results indicate that it is possible to embed bioactive glass particles into carboxymethyl cellulose–dextran hydrogels, and upon submersion in aqueous media, release ions from the glass particles that may elicit therapeutic effects.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Bone Tissue Engineering Materials · Dental materials and restorations · Dental Implant Techniques and Outcomes
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Inamori School of Engineering, Alfred University, Alfred, NY, USA
References (54)
Show source-provided references
1. 10.1016/j.msec.2013.06.01310.1016/j.msec.2013.06.013 ↗
2. 10.1016/j.jocn.2008.02.00910.1016/j.jocn.2008.02.009 ↗
3. 10.1016/j.injury.2011.06.01110.1016/j.injury.2011.06.011 ↗
4. 10.1002/jbm.82007030410.1002/jbm.820070304 ↗
5. 10.1002/1097-4636(200105)55:2<151::AID-JBM1001>3.0.CO;2-D10.1002/1097-4636(200105)55:2<151::AID-JBM1001>3.0.CO;2-D ↗
6. 10.1128/AAC.46.6.1940-1945.200210.1128/AAC.46.6.1940-1945.2002 ↗
7. 10.1016/S0142-9612(99)00201-X10.1016/S0142-9612(99)00201-X ↗
8. 10.1007/BF0240940910.1007/BF02409409 ↗
9. 10.1126/science.167.3916.27910.1126/science.167.3916.279 ↗
10. 10.1177/0022034592071003060110.1177/00220345920710030601 ↗
11. 10.1111/j.1151-2916.1991.tb07132.x10.1111/j.1151-2916.1991.tb07132.x ↗
12. 10.1016/j.bone.2009.07.08210.1016/j.bone.2009.07.082 ↗
13. 10.1016/8756-3282(96)00141-X10.1016/8756-3282(96)00141-X ↗
14. 10.1097/00003086-197210000-0003410.1097/00003086-197210000-00034 ↗
15. 10.1200/JCO.1987.5.2.29210.1200/JCO.1987.5.2.292 ↗
16. 10.1016/0140-6736(90)90540-L10.1016/0140-6736(90)90540-L ↗
17. Bockman RS · J Clin Endocrinol Metab · 1995 · 80 · 595
18. 10.1128/IAI.68.10.5619-5627.200010.1128/IAI.68.10.5619-5627.2000 ↗
19. 10.1172/JCI3078310.1172/JCI30783 ↗
20. 10.1073/pnas.68.7.162310.1073/pnas.68.7.1623 ↗
21. 10.1002/1097-0142(19830601)51:11<1982::AID-CNCR2820511104>3.0.CO;2-L10.1002/1097-0142(19830601)51:11<1982::AID-CNCR2820511104>3.0.CO;2-L ↗
22. 10.1182/blood.V104.11.2487.248710.1182/blood.V104.11.2487.2487 ↗
23. 10.1093/jnci/83.21.158210.1093/jnci/83.21.1582 ↗
24. 10.1200/JCO.1997.15.6.244910.1200/JCO.1997.15.6.2449 ↗
25. 10.1002/adfm.20070093110.1002/adfm.200700931 ↗
26. 10.1177/088532821557195210.1177/0885328215571952 ↗
27. 10.1007/s10853-013-7211-210.1007/s10853-013-7211-2 ↗
28. Valiathan M · Natl Med J India · 1999 · 12 · 270
29. 10.1007/s10856-009-3936-510.1007/s10856-009-3936-5 ↗
30. 10.1089/ten.tea.2012.070710.1089/ten.tea.2012.0707 ↗
31. 10.1007/s10856-005-3578-110.1007/s10856-005-3578-1 ↗
32. 10.1016/j.actbio.2007.07.01010.1016/j.actbio.2007.07.010 ↗
33. 10.1007/s10856-007-3287-z10.1007/s10856-007-3287-z ↗
34. 10.1007/s10856-012-4624-410.1007/s10856-012-4624-4 ↗
35. 10.1016/j.joen.2007.06.01210.1016/j.joen.2007.06.012 ↗
36. 10.1016/0267-6605(90)90052-W10.1016/0267-6605(90)90052-W ↗
37. 10.4155/fmc.11.13410.4155/fmc.11.134 ↗
38. 10.2106/00004623-199404000-0001310.2106/00004623-199404000-00013 ↗
39. 10.1016/j.ijpharm.2008.11.00810.1016/j.ijpharm.2008.11.008 ↗
40. 10.1016/S0142-9612(03)00267-910.1016/S0142-9612(03)00267-9 ↗
41. 10.1089/ten.tea.2008.011010.1089/ten.tea.2008.0110 ↗
42. 10.1039/C2DT32235H10.1039/C2DT32235H ↗
43. 10.1016/j.jconrel.2007.05.02310.1016/j.jconrel.2007.05.023 ↗
44. 10.1016/j.biomaterials.2009.11.01610.1016/j.biomaterials.2009.11.016 ↗
45. 10.1002/(SICI)1097-4636(199911)47:2<152::AID-JBM5>3.0.CO;2-I10.1002/(SICI)1097-4636(199911)47:2<152::AID-JBM5>3.0.CO;2-I ↗
46. 10.1016/0032-3861(93)90600-F10.1016/0032-3861(93)90600-F ↗
47. International Standard 10993-5:1999. Biological evaluation of medical devices part 5: tests for in Vitro Cytotoxicity. Case Postale 56 [CH-1211].
48. 10.1002/adma.20080210610.1002/adma.200802106 ↗
49. 10.1016/j.addr.2012.09.01010.1016/j.addr.2012.09.010 ↗
50. 10.1016/0923-1137(94)00096-N10.1016/0923-1137(94)00096-N ↗
51. 10.1007/s10853-015-9442-x10.1007/s10853-015-9442-x ↗
52. 10.1201/978058541804910.1201/9780585418049 ↗
53. 10.1016/j.biomaterials.2005.01.00610.1016/j.biomaterials.2005.01.006 ↗
54. 10.1016/j.cbi.2007.03.00210.1016/j.cbi.2007.03.002 ↗